ArticleFrontiers in nephrology2026
Case Report: Advanced IgA nephropathy with psoriasis and a complex clinicopathologic course.
Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis and IgA nephropathy are immune-mediated disorders that may coexist, but the clinical meaning of this association remains uncertain. We report a 45-year-old man with psoriasis and progressive kidney dysfunction whose biopsy-proven IgA nephropathy presented with severe impairment of kidney function, heavy proteinuria, and mixed active and chronic histologic injury. At reassessment, serum creatinine was 463 μmol/L, estimated glomerular filtration rate was 12.1 mL/min/1.73 m², and pretreatment 24-hour urinary protein excretion ranged from 2.90 to 4.70 g. Kidney biopsy showed proliferative sclerosing IgA nephropathy, Oxford classification M1E1S1T2C0, with ischemic glomerular injury, microangiopathy, tubular atrophy, and interstitial fibrosis. Targeted-release budesonide and deucravacitinib were started together. Proteinuria fell to 0.62 g, serum creatinine decreased to 323 μmol/L, and a modest improvement in cutaneous disease activity was observed, with PASI decreasing from 2.4 to 1.6. After patient-initiated discontinuation of deucravacitinib, proteinuria increased and later declined after reintroduction. Following completion of the planned budesonide course, proteinuria continued to fall during deucravacitinib monotherapy, while kidney function deteriorated. This case is best interpreted as a clinicopathologic observation rather than proof of drug efficacy. Biopsy-defined activity and chronicity helped explain the discordant changes in proteinuria and kidney function, while the longitudinal course generated a testable but unproven hypothesis of a possible inflammatory connection between psoriasis and IgA nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.